Search clinical trials for: Bevacizumab

Total 2657 results

Vall d'Hebron Institute of Oncology

Recruiting

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)

Ovarian Cancer

Spain
West China Hospital

Not yet recruiting

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Huihua Xiong

Not yet recruiting

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Breasr Cancer
Tianshu Liu

Not yet recruiting

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Not yet recruiting

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
West China Hospital

Not yet recruiting

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
West China Hospital

Not yet recruiting

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Chang Gung Memorial Hospital

Not yet recruiting

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma (PhotonAB)

Hepatocellular Carcinoma

Taiwan
Hansoh BioMedical R&D Company

Not yet recruiting

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Gruppo Oncologico del Nord-Ovest

Recruiting

Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (HAITI)

Colorectal Cancer Metastatic

Italy
NaviFUS Corporation
NaviFUS US LLC

Not yet recruiting

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Glioma | Neoplasms | Glioblastoma | Neoplasms, Nerve Tissue | Brain Tumor | Glioblastoma Multiforme

United States
European Organisation for Research and Treatment...
Novartis

Not yet recruiting

177Lu-DOTATATE for Recurrent Meningioma (LUMEN-1)

Recurrent Meningioma
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Pardis Noor Medical Imaging and Cancer Center

Not yet recruiting

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Cancer | Metastatic Cancer | Liver Metastases
Laboratorios Liomont
Servicios Especializados en Ensayos Clínicos, S.C.

Recruiting

Safety of Effivia®, a Bevacizumab Biosimilar

Metastatic Colorectal Cancer | Metastatic Cervical Cancer | Non Squamous Non Small Cell Lung Cancer

Mexico
Fudan University

Not yet recruiting

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
Lebanese University
Haykel Hospital

Recruiting

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (PTST_PALBEVA)

Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Chemotherapy | Solid Tumor | Immunotherapy | Targeted Therapy | Precision Therapy

Lebanon
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
Henan Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
University of Alabama at Birmingham

Not yet recruiting

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Hepatocellular Carcinoma

United States
Fudan University

Recruiting

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
The Fourth Affiliated Hospital of Zhejiang University...

Recruiting

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

China
Sun Yat-sen University

Recruiting

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Colorectal Cancer | Liver Metastases

China
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Sir Run Run Shaw Hospital

Recruiting

The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma | Pulmonary Metastases | Bevacizumab | Liver Cancer Stage IV | Cryoablation | Cadonilimab

China
Fondation Ophtalmologique Adolphe de Rothschild

Not yet recruiting

Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations (BevacizuMAV)

Cerebral AV Malformation
Nicholas DeVito, MD
Gateway for Cancer Research; Agenus Inc.

Not yet recruiting

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Colorectal Cancer

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma (IMMUNO-TH)

Liver Transplant | Hepatocellular Carcinoma Recurrent | Systemic Treatment
Amgen

Not yet recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Metastatic Colorectal Cancer
UNICANCER
Servier

Not yet recruiting

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (TRIFLUOX-DP)

Metastatic Colorectal Cancer | Metastatic Gastroesophageal Adenocarcinoma | DPD Deficiency
Institute of Liver and Biliary Sciences, India

Not yet recruiting

Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma

India
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Qianfoshan... and other collaborators

Recruiting

Second-line Treatment of Metastatic Colorectal Cancer (BEV-TASIRI)

Metastatic Colorectal Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Cervical Carcinoma

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Tumor

China
Changsha Taihe Hospital

Not yet recruiting

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Shanghai Zhongshan Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fudan University

Recruiting

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | Cadonilimab

China
Fudan University

Not yet recruiting

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Brain Metastasis | TNBC

China
Chinese PLA General Hospital

Recruiting

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Colorectal Neoplasms | Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Metastatic Colorectal Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Harbin Medical University

Not yet recruiting

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Colorectal Cancer
Outlook Therapeutics, Inc.

Recruiting

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States

3

Subscribe